Nucleoside Phosphonate Salts

• US 20130035313A1
• Filed: 02/14/2011
• Published: 02/07/2013
• Est. Priority Date: 02/12/2010
• Status: Active Grant

• Current Assignee: Chimerix Incorporated
• Original Assignee: Chimerix Incorporated
• Inventors: Almond, Merrick, Lanier, Ernest Randall, Ware, Roy W., Lampert, Bernhard
• Granted Patent: US 9,006,218 B2
• Time in Patent Office: Days
• US Class Current: 514/81
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/52 Purines, e.g. adenine
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07D 473/34 attached in position 6, e.g. adenine
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Abstract

The present invention relates to compounds and methods for treating viral diseases. Some compounds of the invention are described by Formula I: (I), wherein M⁺ is Na⁺, Li⁺, K⁺, Ca²⁺, Mg²⁺, or NR_cR_dR_eR_f⁺ and R_c, R_d, R^e and R^f are each independently hydrogen or C_1-5 alkyl, or a stereoisomer, a diastereomer, an enantiomer or racemate thereof.

Claims

1. A compound of formula I:

2. The compound of claim 1 having the structure:

3. The compound of claim 1, wherein M⁺ is K⁺.

22. The compound of claim 1, wherein the compound is anhydrous or is in solvate or hydrate form.

25. The compound of claim 1, wherein the compound is in crystalline form.

4. A pharmaceutical composition comprising a compound of formula I:

5. The pharmaceutical composition of claim 4, wherein the compound has the structure:

6. The pharmaceutical composition of claim 5, wherein M⁺ is K⁺.

18. The pharmaceutical composition of claim 5, wherein the compound has purity greater than 96%.

19. The pharmaceutical composition of claim 5, wherein the compound has purity greater than 97%.

20. The pharmaceutical composition of claim 5, wherein the compound has purity greater than 98%.

21. The pharmaceutical composition of claim 5, wherein the compound has purity greater than 99%.

23. The pharmaceutical composition of claim 4, wherein the compound is anhydrous or is in solvate or hydrate form.

24. The pharmaceutical composition of claim 5, wherein ihe compound is anhydrous or is in solvate or hydrate form.

26. The pharmaceutical composition of claim 4, wherein the compound Is in crystalline form.

27. The pharmaceutical composition of claim 5, wherein the compound is in crystalline form.

7. A method of treating a viral disease comprising administering to a subject an effective amount of a compound of formula I:

8. The method of claim 7, wherein the compound has the structure:

9. The method of claim 8, wherein M⁺ is K⁺.

10-17. -17. (canceled)

28. A compound of formula I: